Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy of the pleura,
with a strong causal link to asbestos exposure. MPM incidence has been increasing in …

Malignant pleural mesothelioma (MPM) is an uncommon disease most often associated with
occupational asbestos exposure and is steadily increasing in worldwide incidence. Patients …

Background: The aim of this open label phase II study (NCT00407459) was to assess the
activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined …

Targeted treatment is a therapy directed at a specific molecular target close to a hallmark of
cancer. The target should be measurable with a biomarker and measurement of the target …

Malignant pleural effusion (MPE) represents 15–35% of pleural effusions and markedly
worsens the prognosis and quality of life of patients with cancer. Malignant mesothelioma …

This review aims to provide insight into treatment of malignant pleural mesothelioma (MPM)
considering effects on survival, quality of life (QoL) and costs, in order to determine the value …

Maligni mezoteliom uvrščamo med redke rake, njegova incidenca pa še vedno narašča pri
nas in v svetu. V Sloveniji smo zakonsko prepovedali proizvodnjo in uporabo azbesta leta …

Personalizing treatment for malignant pleural mesothelioma Cover Page The handle http://hdl.
handle. net/1887/137746 holds various files of this Leiden University dissertation. Author …

Malignant pleural mesothelioma continues to challenge clinicians and scientists, since its
incidence is rising and prognosis is far from favorable. Currently, the standard treatment …

Overview Malignant pleural mesothelioma is an aggressive malignancy with an incidence
that may be peaking worldwide in the next 5–10 years. While the majority of patients do …